Physician profile
Tony A Gore
NPI 1780766881
$11,419.34
in general payments reported to CMS, 2019-2025
10 companies · $41.84 in 2025
The $41.84 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $101 · 2021: $219 · 2022: $120 · 2023: $22.02 · 2024: $45.75 · 2025: $41.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $55.07 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $55.07 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $10,954.81 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $151.60 | 2019-2024 | Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $89.13 | 2021-2022 | |
| Lundbeck LLC | $62.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $54.54 | 2024-2025 | Cobenfy |
| Allergan, INC. | $39.05 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $28.02 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.29 | 2019 | |
| Vanda Pharmaceuticals INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Gore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.